CA2651898A1
(en)
|
2006-04-07 |
2007-10-18 |
Develogen Aktiengesellschaft |
Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
|
EP1889847A1
(de)
|
2006-07-10 |
2008-02-20 |
DeveloGen Aktiengesellschaft |
Pyrrolopyrimidine zur pharmazeutischen Anwendung
|
GB0625659D0
(en)
|
2006-12-21 |
2007-01-31 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
US8653262B2
(en)
|
2007-05-31 |
2014-02-18 |
Boehringer Ingelheim International Gmbh |
CCR2 receptor antagonists and uses thereof
|
WO2009053737A2
(en)
|
2007-10-25 |
2009-04-30 |
Astrazeneca Ab |
Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
|
US20100247517A1
(en)
*
|
2007-11-22 |
2010-09-30 |
Boehringer Ingelheim Internationational GmbH |
Use of mnk inhibitors for the treatment of alzheimer's disease
|
JP2011511005A
(ja)
*
|
2008-02-04 |
2011-04-07 |
オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド |
2−アミノピリジン系キナーゼ阻害薬
|
EA014100B1
(ru)
*
|
2008-02-21 |
2010-08-30 |
Общество С Ограниченной Ответственностью "Валексфарм" |
Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
|
AR072297A1
(es)
|
2008-06-27 |
2010-08-18 |
Novartis Ag |
Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
|
WO2010023181A1
(en)
|
2008-08-26 |
2010-03-04 |
Boehringer Ingelheim International Gmbh |
Thienopyrimidines for pharmaceutical compositions
|
JP5702293B2
(ja)
|
2008-11-10 |
2015-04-15 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物
|
JP2012512834A
(ja)
|
2008-12-19 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
炎症、喘息及びcopdの処置のためのccr2受容体アンタゴニストとしての環状ピリミジン−4−カルボキサミド
|
SG10201607592PA
(en)
|
2008-12-19 |
2016-11-29 |
Vertex Pharma |
Pyrazine derivatives useful as inhibitors of atr kinase
|
US9260730B2
(en)
|
2009-05-07 |
2016-02-16 |
Aquatech Bioenergy LLC |
Method and system for collecting ethanol from aquatic plants
|
CN102933579B
(zh)
|
2009-12-17 |
2015-07-15 |
贝林格尔.英格海姆国际有限公司 |
新的ccr2受体拮抗剂及其用途
|
EA201201192A1
(ru)
|
2010-02-26 |
2013-04-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
|
US8754079B2
(en)
|
2010-02-26 |
2014-06-17 |
Boehringer Ingelheim International Gmbh |
Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
|
UY33241A
(es)
|
2010-02-26 |
2011-09-30 |
Boehringer Ingelheim Int |
?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
|
US9062008B2
(en)
|
2010-05-12 |
2015-06-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
WO2011141474A1
(en)
|
2010-05-12 |
2011-11-17 |
Boehringer Ingelheim International Gmbh |
Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
|
US9334244B2
(en)
|
2010-05-12 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
JP5836367B2
(ja)
|
2010-05-12 |
2015-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼ阻害剤として有用な化合物
|
EP2569295B1
(de)
|
2010-05-12 |
2014-11-19 |
Boehringer Ingelheim International GmbH |
Neue ccr2-rezeptorantagnonisten, herstellungsverfahren dafür und verwendung davon als medikamente
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
CN102947272A
(zh)
|
2010-05-12 |
2013-02-27 |
沃泰克斯药物股份有限公司 |
用作atr激酶抑制剂的2-氨基吡啶衍生物
|
JP2013526538A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
WO2011144501A1
(en)
|
2010-05-17 |
2011-11-24 |
Boehringer Ingelheim International Gmbh |
Ccr2 antagonists and uses thereof
|
WO2011147772A1
(en)
|
2010-05-25 |
2011-12-01 |
Boehringer Ingelheim International Gmbh |
Ccr2 receptor antagonists
|
EP2576538B1
(de)
|
2010-06-01 |
2015-10-28 |
Boehringer Ingelheim International GmbH |
Neue CCR2-Antagonisten
|
JP2013529643A
(ja)
|
2010-06-23 |
2013-07-22 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用なピロロピラジン誘導体
|
CN103429582A
(zh)
*
|
2011-03-04 |
2013-12-04 |
莱西肯医药有限公司 |
Mst1激酶抑制剂及其用法
|
WO2012138938A1
(en)
|
2011-04-05 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Aminopyrazine compounds useful as inhibitors of tra kinase
|
WO2012156367A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Bayer Intellectual Property Gmbh |
Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
|
EP2714692B1
(de)
*
|
2011-06-01 |
2017-03-22 |
Bayer Intellectual Property GmbH |
Substituierte aminoimidazopyridazine
|
WO2012178124A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
EP2723745A1
(de)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Als art-kinasehemmer nützliche verbindungen
|
WO2013010839A1
(en)
|
2011-07-15 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Novel and selective ccr2 antagonists
|
UA117092C2
(uk)
|
2011-09-06 |
2018-06-25 |
Байєр Інтеллектуал Проперті Гмбх |
Амінозаміщені імідазопіридазини
|
ES2711777T3
(es)
|
2011-09-14 |
2019-05-07 |
Samumed Llc |
Indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de Wnt/b-catenina
|
US8765751B2
(en)
|
2011-09-30 |
2014-07-01 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
BR112014007721B1
(pt)
|
2011-09-30 |
2022-11-01 |
Vertex Pharmaceuticals Incorporated |
Processos para preparar compostos úteis como inibidores de atr quinase
|
BR112014007690B1
(pt)
|
2011-09-30 |
2022-10-04 |
Vertex Pharmaceuticals Incorporated |
Usos de inibidores de atr no tratamento de câncer pancreático e câncer de pulmão de células não pequenas
|
AU2012315611A1
(en)
|
2011-09-30 |
2014-04-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
US8846918B2
(en)
|
2011-11-09 |
2014-09-30 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2776422A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Als atr-kinasehemmer nützliche verbindungen
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2776419B1
(de)
|
2011-11-09 |
2016-05-11 |
Vertex Pharmaceuticals Incorporated |
Pyrazin verbindungen als atr kinase inhibitoren
|
EP2776420A1
(de)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazinverbindungen als atr-kinaseinhibitoren
|
SI2814820T1
(sl)
*
|
2012-02-17 |
2016-10-28 |
University Of Cape Town |
Sredstva proti malariji
|
GB201205669D0
(en)
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
CA2869309C
(en)
|
2012-04-05 |
2021-02-09 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
EP2904406B1
(de)
|
2012-10-04 |
2018-03-21 |
Vertex Pharmaceuticals Incorporated |
Verfahren zur bestimmung der durch atr-inhibition auftretenden vermehrten dna-schädigung
|
WO2014062604A1
(en)
|
2012-10-16 |
2014-04-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
ES2635262T3
(es)
|
2012-11-09 |
2017-10-03 |
Evotec International Gmbh |
Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas
|
CN104797585B
(zh)
|
2012-11-19 |
2017-08-15 |
拜耳医药股份公司 |
氨基咪唑并哒嗪
|
AU2013348009C1
(en)
|
2012-11-21 |
2019-08-08 |
Ptc Therapeutics, Inc. |
Substituted reverse pyrimidine Bmi-1 inhibitors
|
ES2884030T3
(es)
|
2012-12-07 |
2021-12-10 |
Vertex Pharma |
2-amino-N-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa
|
MX370487B
(es)
|
2013-01-08 |
2019-12-16 |
Samumed Llc |
Inhibidores de 3-(benzo-imidazol-2-il)-indazol de la senda de señalización de wnt y usos terapéuticos de los mismos.
|
KR102202516B1
(ko)
|
2013-01-23 |
2021-01-12 |
아스트라제네카 아베 |
화합물
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
NZ748260A
(en)
|
2013-08-30 |
2020-01-31 |
Ptc Therapeutics Inc |
Substituted pyrimidine bmi-1 inhibitors
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
WO2015082324A1
(en)
|
2013-12-04 |
2015-06-11 |
Boehringer Ingelheim International Gmbh |
Sulfoximine substituted quinazolines for pharmaceutical compositions
|
JP6543252B2
(ja)
|
2013-12-06 |
2019-07-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体
|
WO2015091156A1
(en)
|
2013-12-17 |
2015-06-25 |
Boehringer Ingelheim International Gmbh |
Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
|
CA2944103A1
(en)
|
2014-05-07 |
2015-11-12 |
Evotec International Gmbh |
Sulfoximine substituted quinazolines for pharmaceutical compositions
|
RS60013B1
(sr)
|
2014-06-05 |
2020-04-30 |
Vertex Pharma |
Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
|
SG10201811175WA
(en)
|
2014-06-17 |
2019-01-30 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
TWI713455B
(zh)
*
|
2014-06-25 |
2020-12-21 |
美商伊凡克特治療公司 |
MnK抑制劑及其相關方法
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
US9862701B2
(en)
|
2014-09-25 |
2018-01-09 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2016049565A1
(en)
*
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
WO2016130501A1
(en)
|
2015-02-09 |
2016-08-18 |
Incyte Corporation |
Aza-heteroaryl compounds as pi3k-gamma inhibitors
|
WO2016140501A1
(en)
*
|
2015-03-04 |
2016-09-09 |
Kainos Medicine, Inc. |
Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
|
US10246424B2
(en)
|
2015-04-10 |
2019-04-02 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
EP3283462B1
(de)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Kondensierte tricyclische inhibitoren von kras und anwendungsverfahren dafür
|
WO2017004537A1
(en)
|
2015-07-02 |
2017-01-05 |
Centrexion Therapeutics Corporation |
(4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
WO2017024010A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
US10206909B2
(en)
|
2015-08-03 |
2019-02-19 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024026A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023980A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10285983B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
|
US10383861B2
(en)
|
2015-08-03 |
2019-08-20 |
Sammumed, LLC |
3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024025A1
(en)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
WO2017023989A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023993A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017024021A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
EP3356349A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356359B1
(de)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356347A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356339A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3356351A1
(de)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitoren von kras-g12c-mutanten proteinen
|
EP3355926A4
(de)
|
2015-09-30 |
2019-08-21 |
Vertex Pharmaceuticals Inc. |
Verfahren zur behandlung von krebs mit einer kombination von dna-schädigenden mitteln und atr-inhibitoren
|
JP2018533939A
(ja)
|
2015-10-19 |
2018-11-22 |
アラクセス ファーマ エルエルシー |
Rasの阻害剤をスクリーニングするための方法
|
PL3371190T3
(pl)
|
2015-11-06 |
2022-11-07 |
Incyte Corporation |
Związki heterocykliczne jako inhibitory pi3k-gamma
|
US10544139B2
(en)
|
2015-11-06 |
2020-01-28 |
Samumed, Llc |
Treatment of osteoarthritis
|
CA3005089A1
(en)
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
EP3400221B1
(de)
|
2016-01-05 |
2020-08-26 |
Incyte Corporation |
Pyrazol und imidazol substituierte pyridine als pi3k-gamma-hemmstoffe
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
WO2017223414A1
(en)
|
2016-06-24 |
2017-12-28 |
Incyte Corporation |
HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
CN110312711A
(zh)
|
2016-10-07 |
2019-10-08 |
亚瑞克西斯制药公司 |
作为ras抑制剂的杂环化合物及其使用方法
|
CA3041291A1
(en)
|
2016-10-21 |
2018-04-26 |
Samumed, Llc |
Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
|
US10758523B2
(en)
|
2016-11-07 |
2020-09-01 |
Samumed, Llc |
Single-dose, ready-to-use injectable formulations
|
WO2018140512A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
US11059819B2
(en)
|
2017-01-26 |
2021-07-13 |
Janssen Biotech, Inc. |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
WO2018140514A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
EP3573964A1
(de)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Benzothiophen- und benzothiazolverbindungen und verfahren zur verwendung davon
|
SG11201907356SA
(en)
|
2017-02-14 |
2019-09-27 |
Effector Therapeutics Inc |
Piperidine-substituted mnk inhibitors and methods related thereto
|
US10736897B2
(en)
|
2017-05-25 |
2020-08-11 |
Araxes Pharma Llc |
Compounds and methods of use thereof for treatment of cancer
|
MX2019013954A
(es)
|
2017-05-25 |
2020-08-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras.
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
LT3697789T
(lt)
|
2017-10-18 |
2021-12-10 |
Incyte Corporation |
Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
|
WO2019126505A1
(en)
|
2017-12-21 |
2019-06-27 |
Incyte Corporation |
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as pi3k-gamma kinase inhibitors for treating e.g. cancer
|
CN112088157B
(zh)
|
2017-12-22 |
2023-12-26 |
拉文纳制药公司 |
作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物
|
EP3762368B1
(de)
|
2018-03-08 |
2022-01-26 |
Incyte Corporation |
Aminopyrazindiolverbindungen als pi3k-y-hemmer
|
US11046658B2
(en)
|
2018-07-02 |
2021-06-29 |
Incyte Corporation |
Aminopyrazine derivatives as PI3K-γ inhibitors
|
FI3847175T3
(fi)
|
2018-09-05 |
2024-03-22 |
Incyte Corp |
Fosfoinositidi-3-kinaasin (pi3k) inhibiittorin kiteisiä muotoja
|
KR20210102211A
(ko)
|
2018-10-24 |
2021-08-19 |
이펙터 테라퓨틱스, 인크. |
Mnk 억제제의 결정질 형태
|
IL310590A
(en)
*
|
2021-08-05 |
2024-04-01 |
4E Therapeutics Inc |
Methods of treating migraine with MNK inhibitors
|